Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692860 | 0.85 | DPP4 (0.43) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL8238467 | 0.83 | DPP4 (0.44) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL28183895 | 0.81 | DPP4 (0.49) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3973347 | 0.80 | DPP4 (0.47) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL5813062 | 0.78 | DPP4 (0.46) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL4981480 | 0.77 | DPP4 (0.43) | DPP4DPP9DPP7DPP8RIPK1 | |
| SCHEMBL5794436 | 0.76 | TRPA1 (0.50) | FFAR1 | |
| SCHEMBL14687291 | 0.76 | ALDH1A1 (0.43) | DPP4DPP9DPP7 | |
| SCHEMBL13172944 | 0.76 | DPP4 (0.40) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL451227 | 0.75 | DPP4 (0.47) | DPP4DPP9DPP7DPP8RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-1976843-B1 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | BACE1, PSEN1, BACE2 | DPP4 3022/4885DPP9 2255/4885DPP7 2048/4885 |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | BACE1, BACE2, PSEN1 | DPP4 2857/4885DPP9 1949/4885DPP7 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.